Polymer-Drug Conjugates: Novel Carriers for Cancer Chemotherapy

Cancer is the second worldwide cause of death following cardiovascular diseases. Chemotherapy is the gold standard strategy for effective treatment of cancer. However, the use of free chemotherapeutic agents in cancer treatment has been hindered by poor aqueous solubility, short biological half-life, non-speci?city or dose-dependent cellular toxicity, and the development of multidrug resistance. To address the aforementioned limitations, polymer-drug conjugations, among other novel drug delivery approaches, are receiving attention in cancer therapy. In this review the concept of polymer–drug conjugations, polymer–drug conjugates as drug carriers, polymer-drug coupling methods, and recent polymer-anticancer drugs conjugates have been described.     

Interaction,Controlled Release,and Antitumor Activity of Doxorubicin Hydrochloride From pH-Sensitive P(NIPAAm-MAA-VP) Nanofibrous Scaffolds Prepared by Green Electrospinning

Biocompatible and pH-sensitive poly (N-isopropylacrylamide-co-methacrylic acide-co-vinylpyrrolidone) [P(NIPAAm-MAA-VP)] nanofibers were prepared as a delivery vehicle for sustained release of doxorubicin hydrochloride (DOX) as an anticancer drug. The structure and morphology of nanofibers were investigated by SEM, FTIR, and XRD. P(NIPAAm-MAA-VP)–DOX complex was formed at pH 7 because of ionic interactions between DOX and polymers. P (NIPAAm-MAA-VP) nanofibers tailored to desire diameters with bead free morphology by optimizing the electrospinning parameters DOX release from P (NIPAAm-MAA-VP)/DOX complex was investigated as a biological on–off switch for the design of an intelligent drug delivery system triggered by external pH changes.     

Synthesis,Characterization, and Viscoelastic Behavior of Thermothickening Poly (N-Isopropylacrylamide-Methacrylicacide-Vinylpyrrolidone) Nanogels as an Injectable Biocompatible Drug Carrier

In the present work, the preparation of dual thermo-/pH-responsive nanogels composed poly (NIPAAm-MAA-VP) was investigated as an injectable carrier in which doxorubicin hydrochloride (DOX) was opted as an anticancer agent. The SEM photomicrographs showed that copolymer was almost spherical in shape with the mean diameter below 30 nm. Using dynamic oscillatory the gel-like behavior was observed at 37°C for the crosslinked polymer. Biocompatibility of the synthesized nanoparticles and superior antitumor activity of DOX-loaded nanoparticles were proved by in vitro cytotoxicity assay. The system is expected to be valuable for the delivery of chemotherapeutic agents in the treatment of solid tumors.     

Isolation and structural characterisation of five new and 14 known metabolites from the commercial starfish Archaster typicus

From the commercially available starfish Archaster typicus, five new (1–5) and 14 known (6–19) metabolites were isolated and identified. Detailed 1D and 2D NMR spectroscopic data, including ¹H, ¹³C, DEPT, HSQC, HMBC, and NOESY, established the structures of the new metabolites as sodium 5α-cholesta-9(11),24-dien-3β,6α,20β-triol-23-one 3-sulphate (1), sodium 5α-cholesta-9(11)-en-3β,6α,20β-triol-23-one 3-sulphate (2), sodium (25R)-5α-cholestane-3β,4β,6α,8,14α,15β,26-heptaol-15-sulphate (3), sodium (25R)-5α-cholestane-3β,6α,8,14α,15β,26-hexaol 15-sulphate (4), and sodium cholest-25(27)-ene-3β,4β,5α,6α,7β,8β,14α,15α,24,26-decanol 6-sulphate (5). Other spectroscopic techniques, including IR, ESI–MS, and HR-ESI–MS, were also adopted to further confirm the structures of the metabolites. These five steroids (1–5) are reported in nature for the first time. All of the steroids found in A. typicus (1–12) were tested for anticancer activities against MDA-MB-435 and Colo205 tumour cells. However, only sodium 5α-cholesta-9(11)-en-3β,6α,20β-triol-23-one 3-sulphate (2) and 27-nor-5α-cholestane-3β,4β,5,6α,7β,8,14,15α,24α-nonaol (6) exhibited weak activities.     

Synthesis,characterization, biological evaluation,and drug release study of polyamidoamine-containing neridronate

Polyamidoamines were synthesized by Michael-type polyaddition reaction and conjugates characterized by ¹H NMR, ³¹ Mosmann, T. Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays. J. Immunol. Meth. 1983, 65, 55–63.[Crossref], [PubMed], [Web of Science ®] , [Google Scholar]P NMR, FTIR, SEM, and EDX. The biological evaluation of the new materials revealed 12–30% inhibition of the human breast cancer cells (MCF7) and 25% of the Plasmodium falciparum malaria parasites by the conjugates. The hemolysis assay revealed that these materials did not have any effect on the host red blood cell membrane. The release mechanism of neridronate followed Korsmeyer–Peppas model at pH 1.2 with a diffusion coefficient of 0.45 indicating a Fickian diffusion mechanism; Higuchi model at pH 6.0 thus indicating a diffusion mechanism.     

电导法测定铂抗癌药物的解离速率

根据铂抗癌药物的解离反应特征，建立了以电导法测定其解离速率的原理和方法，具有操作简单、数据准确的优点，可用作研究这类药物的稳定性。     

A theoretical study on mechanism of the anticancer drug camptothecin's E-ring-opening

A reaction mechanism of the anticancer agent camptothecin (CPT)’s E-ring-opening has been studied by DFT method and IEF-PCM solvation model. Our results indicate that under the physiological PH, CPT's E-ring-opening is a spontaneous process, and it conforms to the addition coupled elimination reaction pathway with a proton translocation. The obtained activation free energies in the explicit water model are in agreement with the available experimental values. More than ten reactions have been studied to provide exhaustive analyses of the relationship between structure and reactivity. On the whole, our results accord with the experimental findings and the mechanism we proposed is reasonable.     

Macromolecular Antiproliferative Agents Featuring Dicarboxylato-Chelated Platinum

Cancerous diseases, together with cardiac afflictions, account for the predominant causes of death among the adult population of the Western world. The classical platinum drugs, with cisplatin as their parent, have established themselves for years as leading components in the oncologist’s arsenal of antitumor agents. As with most other antineoplastic drugs, however, incisive pharmacological deficiencies, notably excessive systemic toxicity and induction of drug resistance, have severely curtailed their overall efficaciousness. With the objective of overcoming these counterproductive deficiencies, the technique of polymer-drug conjugation, representing an advanced modality of drug delivery, has been developed in recent years to high standards worldwide. In a drug conjugate, water-soluble macromolecular carrier constructs designed in compliance with stringent pharmacological specifications are covalently, yet bioreversibly, interconnected with the bioactive agent. As a macromolecule following a pharmacokinetic pathway different from that of non-polymeric compounds, the conjugate acts as a pro-drug favorably transporting the agent through the various body compartments to, and into, the target cell, where the agent is enzymatically or hydrolytically separated from the carrier for its biological action. In the authors’ laboratories the conjugation strategy has been adopted as the primary tool for drug efficacy enhancement. The present paper describes a special type of platinum complex carrier-bound via dicarboxymetal chelation, synthesized from carboxyl-functionalized polyamide-type carriers by platination with trans-1,2-diaminocyclohexanediaquaplatinum(II) dinitrate. In a series of in vitro tests antiproliferative activities have been determined against several human cancer cell lines. Whereas no improvements are observed in tests against a colorectal cancer, outstanding findings of the screening program include a 10- to 100-fold increase in cell-killing performance of the conjugates relative to the (non-polymeric) cisplatin standard against the HeLa adenocarcinoma, and distinctly reduced resistance factors (again, relative to cisplatin) in tests against the A2780 and A2780-cis pair of ovarian cell lines. These findings augur well for future developments of this class of platinum drugs. This article is dedicated to Professor Astruc.     

Degradable micelles based on hydrolytically degradable amphiphilic graft copolymers for doxorubicin delivery

Micelles based on a low-toxic and hydrolytically degradable poly(β-amino ester)-g-octadecyl acrylate (PAE-g-ODA) amphiphilic copolymer were developed for doxorubicin (DOX) delivery. A two-step reaction pathway was used to synthesize PAE-g-ODA copolymers with poly(ethylene glycol) segments in the backbone via Michael-type addition reaction. Copolymers with various grafting degrees were obtained by tuning the feeding molar ratios of acrylate/formed secondary amine and the grafting reaction time. Among this series of copolymers, PAE-g-ODA-2 (PAE-g-ODA with 45% ODA side chains) were found to form spherical micelles with an average size of 72.5 nm, as determined by dynamic light scattering (DLS) and transmission electron microscope (TEM), whereas the other PAE-g-ODA copolymers fail to form stable micelles with a narrow size distribution in an aqueous solution. The titration curve illustrated that PAE-g-ODA-2 has a high buffer capacity in the pH range of 7.5-5. The hydrolytic degradation of PAE-g-ODA-2 copolymer in PBS buffer (pH 7.4, 37 °C) was monitored by ¹H NMR. It was found that up to 70% ester groups in the backbones were hydrolyzed in 48 h. The DOX-loaded micelles release about 70% trapped DOX within 48 h in physiological condition. Cytotoxicity assay showed a low cytotoxicity of PAE-g-ODA-2 micelles as well as a higher inhibition against HepG2 tumor cells of DOX-loaded micelles than free DOX.